clinical study of positron emission tomography with 3-deoxy-3-[18F]-fluoro-D-glucose
Not Applicable
- Conditions
- healthy adult volunteer, cancer, epilepsy, Moyamoya disease,Alzheimer's disease
- Registration Number
- JPRN-UMIN000008871
- Lead Sponsor
- Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
exclude the patients who are recognized as inadequate patients by doctors with resposibility in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method visualization of the lesion
- Secondary Outcome Measures
Name Time Method Confirmation of the differences between 3FDG-PET and conventional 2FDG-PET
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does 3FDG-PET imaging target in Alzheimer's disease and cancer diagnostics?
How does 3FDG-PET compare to FDG-PET in detecting metabolic changes in Moyamoya disease and epilepsy?
What biomarkers are associated with 3FDG-PET response variability in brain tumor and neurodegenerative disease patients?
What adverse events were observed in 3FDG-PET clinical trials for healthy volunteers and cancer patients?
What are the potential applications of 3FDG-PET in combination with other imaging modalities for early cancer detection?